Pure Global AI
NCT06143735Not yet recruiting

A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors

A Randomized, Multicenter, Exploratory Clinical Study for The Primary And Secondary Prevention of Febrile Neutropenia (FN) With Efbemalenograstim Alfa in Patients With Non-small Cell Lung Cancer (NSCLC) at Moderate Risk Undergoing Chemotherapy Regimens With Associated Risk Factors
Tianjin Medical University Cancer Institute and HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non Small Cell Lung Cancer
Drug/Device/Intervention
Efgbemalenograstim alfa
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Tianjin Medical University Cancer Institute and Hospital
Location
Zhengzhou,Wuhan,Hohhot,Shenyang,Xi'an,Jinan,Chengdu,Chengdu,Ningbo,Tianjin, China
Timeline & enrollment
Phase
Phase 2
Start date
Dec 31, 2023
End date
Jun 30, 2026
Enrollment
99 participants
Primary outcome

The incidence rate of Grade ≥3 ANC reduction

Summary

The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the
 prevention of absolute neutrophil count (ANC) reduction after chemotherapy in NSCLC patients
 at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN)

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06143735
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06143735 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 99 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.